Mi SciELO
Servicios Personalizados
Articulo
Indicadores
- Citado por SciELO
Links relacionados
- Similares en SciELO
Compartir
Revista Habanera de Ciencias Médicas
versión On-line ISSN 1729-519X
Resumen
MARTINEZ PORTUONDO, Ana Ivonne et al. Lethality as an influential indicator in the elimination of tuberculosis in Havana. Rev haban cienc méd [online]. 2020, vol.19, n.6 Epub 10-Ene-2021. ISSN 1729-519X.
Introduction:
The proposal of the End TB Strategy is to end tuberculosis by 2035 globally.
Objective:
To determine the lethality of tuberculosis with negative immunodeficiency virus as an indicator in the elimination of the disease.
Material and Method:
A descriptive study on the lethality of cases diagnosed with negative immunodeficiency virus during 2000 and 2015 was conducted in Havana. The study considered the annual cohorts of tuberculosis patients according to age groups, municipalities, variability, tuberculosis, Smear-positive pulmonary tuberculosis (BAAR +), and the retreatments by years. The variation of the disease in the study as well as the variation of pulmonary tuberculosis and the results of sputum microscopies were added to the analysis of lethality carried out in every municipality.
Results:
The case fatality rate of tuberculosis in new cases with negative immunodeficiency virus was 8.8% with a predominance of those who died from Tuberculosis (5.4%). In the cases of retreatments, it was 16.2%. Case fatality increased by 43.5% with 2.9% per year and with age. Those patients who died from pulmonary tuberculosis represented 96.6%. Five municipalities stand out in the results.
Conclusions:
The lethality of tuberculosis in new cases with negative immunodeficiency virus revealed an annual increase in pulmonary tuberculosis and retreatments, suggesting difficulties related to the control of the disease and potentially compromising its elimination in Havana. Intensifying the prevention of influencing factors could reduce this indicator.
Palabras clave : Pulmonary tuberculosis; lethality; indicator; negative human immunodeficiency virus; disease control.